Valbenazine (dihydrochloride)
Valbenazine (NBI-98854) dihydrochloride is a VMAT2 inhibitor, used to treat tardive dyskinesia. Valbenazine dihydrochloride demonstrates potential benefit in alleviating symptoms associated with movement disorders resulting from chronic dopamine receptor blocking medications. Valbenazine dihydrochloride has been supported by evidence from preclinical models examining its role in the genetic factors linked to tardive dyskinesia.
Product Specifications
CAS Number
1639208-51-7
Product Name Alternative
NBI-98854 (dihydrochloride)
UNSPSC
12352005
Target
Dopamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/valbenazine-dihydrochloride.html
Smiles
CC(C)[C@H](N)C(O[C@@H]1C[C@]2([H])C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC(C)C)=O.Cl.Cl
Molecular Formula
C24H40Cl2N2O4
Molecular Weight
491.49
References & Citations
[1]Genetics of tardive dyskinesia: Promising leads and ways forward
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 4
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
UACA / Nucling (AE-5), CF640R conjugate, 0.1mg/mL
